Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2021

01.09.2021 | editorial

Pediatric oncology 2.0—shaping the future with precision

verfasst von: Assoc.-Prof. Dr. Michael Dworzak

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

Achievements in pediatric oncology serve as a role model of what can be attained regarding cure and survival rates with multimodal conventional therapeutic strategies. Dose intensification and density oriented at the maximum tolerable, as well as strict adherence over the last 40 years to sequential series of treatment optimization trials available for most pediatric cancer entities in an internationally collaborative setting were the cornerstones of these achievements. Nevertheless, not every child with cancer nor every entity fares well with this strategy. Treatment burden in terms of amount delivered as well as duration have not changed the output for about 10–20% of children and adolescents overall. We need to think out of the box—most probably through integration of the concepts of personalized medicine: personalized not only by further improvement of risk stratification, as we have already for many years, but personalized based on individualized target definition. Oncologic precision medicine has also arrived in pediatric cancer care. …
Literatur
Metadaten
Titel
Pediatric oncology 2.0—shaping the future with precision
verfasst von
Assoc.-Prof. Dr. Michael Dworzak
Publikationsdatum
01.09.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00740-2